Vireo Growth (VREOF) Consolidated Net Income (2020 - 2026)
Vireo Growth's (VREOF) quarterly Consolidated Net Income came in at -$22.5 million in Q1 2026, down 246.15% year-on-year from $15.4 million in Q1 2025, and up 33.39% quarter-over-quarter from -$33.8 million in Q4 2025.
Vireo Growth (VREOF) Consolidated Net Income (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Consolidated Net Income across 7 years of filings, most recently posting -$22.5 million for Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$22.5 million, down 246.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$97.5 million (down 250.81% YoY), and the FY2025 annual result was -$81.5 million, down 191.06% from the prior year.
- Consolidated Net Income came in at -$22.5 million for Q1 2026 at Vireo Growth, up from -$33.8 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $3.8 million in Q4 2023 to a low of -$33.8 million in Q4 2025.
- The 5-year median for Consolidated Net Income is -$7.4 million (2023), against an average of -$11.0 million.
- Across the five-year window, Consolidated Net Income soared 214.89% in 2023 and tumbled 2134.26% in 2025, its largest moves.
- Vireo Growth's Consolidated Net Income stood at -$3.3 million in 2022, then jumped by 214.89% to $3.8 million in 2023, then slumped by 509.08% to -$15.7 million in 2024, then sank by 115.13% to -$33.8 million in 2025, then jumped by 33.39% to -$22.5 million in 2026.
- The last three Consolidated Net Income figures came in at -$22.5 million (Q1 2026), -$33.8 million (Q4 2025), and -$26.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -114,733.81 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.50 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -14.93 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Jun 30, 2024 | -668,411.00 |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | 3.84 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -7.39 Mn |
| Mar 31, 2023 | -8.47 Mn |
| Dec 31, 2022 | -3.34 Mn |
| Sep 30, 2022 | -9.57 Mn |
| Jun 30, 2022 | -6.10 Mn |
| Mar 31, 2022 | -17.68 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -6.84 Mn |
| Jun 30, 2021 | -6.99 Mn |